anlak storytelling
All kinds
Document kinds
Loading document kinds...

Primary corpus lens for browsing and insights. Selection lives in the URL.

All formats
Orientation
Loading formats...

Landscape, portrait, square, or unknown document geometry.

Unlock
slides · global inventory

Title

Component collection for the active corpus filters, with each row opening the slide detail view.

Search Insights JSON Unlock
Matching slides 303,780
Current window 223,681-223,710
Pages 10,126
Rows per page 30
Component: Titleclear collectionreset all
18 30 60

Component

223,681-223,710 of 303,780

filter-aware
18
Houlihan Lokey | Investor Presentation Deck | 33 slidesHoulihan Lokey | Investor Presentation Deck | 33 slides · Houlihan Lokey
Pitch deck Investor relations Beat · Competition1 hit
20
The slide uses a decomposition of the total M&A market to illustrate the 'Room to Grow' in the mid-cap space.Houlihan Lokey | Investor Presentation Deck | 33 slides · Houlihan Lokey
Pitch deck Investor relations Beat · Competition1 hit
21
Slide 21 of a pitch deck.Houlihan Lokey | Investor Presentation Deck | 33 slides · Houlihan Lokey
Pitch deck Investor relations Beat · Competition1 hit
22
The slide uses competitive benchmarking to establish authority in the restructuring market.Houlihan Lokey | Investor Presentation Deck | 33 slides · Houlihan Lokey
Pitch deck Investor relations Beat · Competition1 hit
23
Includes three award badges for 2023 HFM services.Houlihan Lokey | Investor Presentation Deck | 33 slides · Houlihan Lokey
Pitch deck Investor relations Beat · Financials1 hit
25
Houlihan Lokey | Investor Presentation Deck | 33 slidesHoulihan Lokey | Investor Presentation Deck | 33 slides · Houlihan Lokey
Pitch deck Investor relations Beat · Financials1 hit
26
The slide highlights financial resilience and scalability through market cycles.Houlihan Lokey | Investor Presentation Deck | 33 slides · Houlihan Lokey
Pitch deck Investor relations Beat · Financials1 hit
28
The slide outlines financial discipline and capital allocation priorities.Houlihan Lokey | Investor Presentation Deck | 33 slides · Houlihan Lokey
Pitch deck Investor relations Beat · Financials1 hit
29
Includes detailed line items for compensation, non-compensation, operating income, other income, taxes, net income, and EPS.Houlihan Lokey | Investor Presentation Deck | 33 slides · Houlihan Lokey
Pitch deck Investor relations Beat · Financials1 hit
30
The slide presents four bar charts showing financial performance metrics over six years.Houlihan Lokey | Investor Presentation Deck | 33 slides · Houlihan Lokey
Pitch deck Investor relations Beat · Financials1 hit
31
The slide uses a world map as a background watermark.Houlihan Lokey | Investor Presentation Deck | 33 slides · Houlihan Lokey
Pitch deck Investor relations Beat · Team1 hit
33
Houlihan Lokey | Investor Presentation Deck | 33 slidesHoulihan Lokey | Investor Presentation Deck | 33 slides · Houlihan Lokey
Pitch deck Investor relations 1 hit
02
Immix Biopharma | Investor Presentation Deck | 57 slidesImmix Biopharma | Investor Presentation Deck | 57 slides · Immix Biopharma
Pitch deck Investor relations Beat · Hook1 hit
03
The slide uses a numbered list format to present key value propositions.Immix Biopharma | Investor Presentation Deck | 57 slides · Immix Biopharma
Pitch deck Investor relations Beat · Hook1 hit
04
Uses a hub-and-spoke diagram to illustrate the central problem of CAR-T neurotoxicity and its four primary negative impacts.Immix Biopharma | Investor Presentation Deck | 57 slides · Immix Biopharma
Pitch deck Investor relations Beat · Problem (Identify pain)Loop · Cost Of Inaction1 hit
05
Includes a cartoon mascot at the bottom.Immix Biopharma | Investor Presentation Deck | 57 slides · Immix Biopharma
Pitch deck Investor relations Beat · Problem (Identify pain)Loop · Cost Of Inaction1 hit
06
The slide uses a bar chart combined with a data table to highlight safety advantages. It includes a disclaimer about cross-trial comparisons.Immix Biopharma | Investor Presentation Deck | 57 slides · Immix Biopharma
Pitch deck Investor relations Beat · Situation & ContextLoop · Golden Circle1 hit
07
Uses icon-based visualization to represent market expansion from 5% of hospitals to a much broader network.Immix Biopharma | Investor Presentation Deck | 57 slides · Immix Biopharma
Pitch deck Investor relations Beat · Situation & ContextLoop · Golden Circle1 hit
08
The slide highlights the structural difference of the NXC-201 molecule compared to Abecma, Carvykti, and CART-ddBCMA.Immix Biopharma | Investor Presentation Deck | 57 slides · Immix Biopharma
Pitch deck Investor relations Beat · Situation & ContextLoop · Golden Circle1 hit
10
The slide uses a comparative timeline visualization to highlight the superior safety and efficacy profile of NXC-201.Immix Biopharma | Investor Presentation Deck | 57 slides · Immix Biopharma
Pitch deck Investor relations Beat · Situation & ContextLoop · Golden Circle1 hit
11
The chart illustrates the mechanism of action and efficacy of NXC-201 (formerly HBI0101) in treating AL Amyloidosis.Immix Biopharma | Investor Presentation Deck | 57 slides · Immix Biopharma
Pitch deck Investor relations Beat · Evidence & ProofLoop · Hypothesis Test1 hit
13
The slide uses a dual-metric comparison (Hematologic Response vs. Cardiac Response) to highlight NXC-201's efficacy.Immix Biopharma | Investor Presentation Deck | 57 slides · Immix Biopharma
Pitch deck Investor relations Beat · Evidence & ProofLoop · Hypothesis Test1 hit
14
The slide uses a table structure to contrast treatment efficacy and patient outcomes, with a bar chart at the bottom illustrating patient population growth.Immix Biopharma | Investor Presentation Deck | 57 slides · Immix Biopharma
Pitch deck Investor relations Beat · Evidence & ProofLoop · Hypothesis Test1 hit
15
The slide uses a visual comparison to highlight a 67% improvement in response rates for NXC-201 compared to competitors.Immix Biopharma | Investor Presentation Deck | 57 slides · Immix Biopharma
Pitch deck Investor relations Beat · Evidence & ProofLoop · Hypothesis Test1 hit
17
Includes detailed clinical trial references in the footer.Immix Biopharma | Investor Presentation Deck | 57 slides · Immix Biopharma
Pitch deck Investor relations Beat · VisualizationLoop · Why Now1 hit
18
The slide uses a two-column layout to track progress for two distinct drug programs.Immix Biopharma | Investor Presentation Deck | 57 slides · Immix Biopharma
Pitch deck Investor relations Beat · VisualizationLoop · Why Now1 hit
20
The slide uses a standard pharmaceutical pipeline table format.Immix Biopharma | Investor Presentation Deck | 57 slides · Immix Biopharma
Pitch deck Investor relations Beat · VisualizationLoop · Why Now1 hit
22
The slide uses a wave-like visual to represent market size, with specific dollar amounts associated with different disease categories.Immix Biopharma | Investor Presentation Deck | 57 slides · Immix Biopharma
Pitch deck Investor relations Beat · VisualizationLoop · Why Now1 hit
23
Immix Biopharma | Investor Presentation Deck | 57 slidesImmix Biopharma | Investor Presentation Deck | 57 slides · Immix Biopharma
Pitch deck Investor relations Beat · Desire1 hit
24
The slide uses a red dashed box to highlight the primary efficacy metrics for comparison.Immix Biopharma | Investor Presentation Deck | 57 slides · Immix Biopharma
Pitch deck Investor relations Beat · Desire1 hit